Adherence to Guidelines for Antiretroviral Therapy and for Preventing Opportunistic Infections in HIV-Infected Adults and Adolescents in Ryan White–Funded Facilities in the United States

Je, Kaplan; Dl, Parham; Soto-Torres, Lydia; K, van Dyck; Ja, Greaves; Rauch, Kathryn J.; B, Ellis; He, Amandus

doi:10.1097/00126334-199907010-00008

Cited by 37 publications

(27 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the United States, 19% of a population-based sample of HIV-infected women had not had a Pap-test in the last 12 months, 8 while lack of lifetime Pap-smear was reported in 12% of another group of HIV-infected women. 9 In Italy, Zanetta and colleagues 10 observed that only 1 out of 6 HIV-infected women with ICC received a Pap-smear in the last 24 months and none in the last 12 months. In women of the general population, knowledge about Pap test was shown to be associated with increased use of screening, 11 whereas a low educational level was identified as a risk factor for lack of Pap-test knowledge.…”

mentioning

confidence: 99%

Knowledge and use of papanicolaou test among HIV‐positive women

Serraino

Pavia

Navarra

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Dear Sir,It is well known that women who are infected with the human immunodeficiency virus (HIV) have higher rates of infection with human Papillomaviruses (HPV) 1,2 and that these women present an approximately 10-fold higher risk for invasive cervical cancer (ICC) than age-matched women in the general population. 3 In addition to the high frequency of HPV infection, the increased ICC risk in HIVpositive women could be explained by the immunosuppressive effect of HIV, which may accelerate HPV-related oncogenesis. 4,5 Moreover, because of life-styles often associated with HIV infection (e.g., use of intravenous drugs and prostitution), HIV-positive women may be less likely to receive appropriate cervical screening through Papanicolaou (Pap)-smear than HIV-negative women.In this epidemiological research, we investigated I) the extent to which HIV-infected women were aware that Pap-smear could prevent cervical cancer, ii) factors eventually associated with lack of awareness of Pap-smear, and iii) whether lack of awareness affected the use of Pap-smear screening.A cross-sectional study was conducted between January 2003 and June 2004 at the HIV Outpatient Gynaecological Clinic of the National Institute for Infectious Disease L. Spallanzani, Rome. During this period, 534 HIV-positive women were referred by infectious disease specialists for gynaecological examination, including Pap-smear and, when appropriate, colposcopy. Of these 534 HIV-positive women, 147 were not timely traced. According to a protocol approved by the Ethical Committee of the National Institute for Infectious Disease L. Spallanzani, Rome, 387 women (72.5%) were thus invited to take part in the study. Three hundred eighty-one of them accepted participation and signed the informed consent. Following the aim of this analysis, 44 out of the 381 HIV-positive women who accepted participation were excluded because of missing information on the study endpoint: the remaining 337 HIV-positive women constitute the study group.Relevant information was collected through a questionnaire-based interview that was conducted, before the gynaecological examination, by 2 gynaecologists (CP and GP). To assess awareness of the Pap-smear, study participants were first asked if they were ever told about Pap-smear and, second, if they knew that Pap-smear was a cancer preventive tool. Following the aims of this analysis, women who knew that a Pap-test was used to prevent cervical cancer (or cancer of the uterus) were considered aware of Pap-smear. Other collected data included sociodemographic factors (e.g., age, education and country of origin), smoking and reproductive history, sexual habits (e.g., age at first intercourse, number of partners and contraceptive methods) and history of HIV infection (e.g., date of first seropositive test and mode of HIV acquisition). History of Papsmear was investigated in detail to assess lifetime testing, age at first smear, number of smears done in the 5 years and in the last year preceding the interview, and a self-reported history o...

show abstract

mentioning

confidence: 99%

Knowledge and use of papanicolaou test among HIV‐positive women

Serraino

Pavia

Navarra

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…For example, 1 study reported a 70% vaccination rate for 1411 patients enrolled in 4 states (Maryland, Illinois, New York, and Georgia) under the US Health Resources and Services Administration's Ryan White Title III system. 8 However, these vaccination rates may not be reflective of all Ryan White Title III system clinics, as patients were limited to those seen within the past 6 months and only from study sites with expressed interest in study participation. The Veterans Aging (VA) Cohort 5-Site Study, which aimed to evaluate the impact of PPV23 on the incidence of pneumonia, evaluated vaccination status for 1626 patients.…”

Section: Discussionmentioning

confidence: 99%

“…Regardless, our data show that uptake of the second PPV23 dose is much lower than the first dose, and there are no published studies evaluating uptake of the second PPV23 dose in HIV-infected patients. A recent study highlighted the potential benefit of PPV23 revaccination by demonstrating a significant rise in OPT above previously used vaccine response threshold (8) in HIV-infected patients revaccinated with PPV23 after 5 years. 21 As a result, the USAF program is conducting quality improvement initiatives, including in-services to educate providers, nursing chart review, and display of immunization schedules in patient examination rooms.…”

Section: Discussionmentioning

confidence: 99%

23-Valent Pneumococcal Polysaccharide Vaccine Uptake in the United States Air Force HIV Program

Ocampo

Matthews

et al. 2016

J Int Assoc Provid AIDS Care

View full text Add to dashboard Cite

Streptococcus pneumoniae infection is a predominant cause of bacterial infection in HIV-infected individuals. However, reported rates of pneumococcal vaccination with 23-valent polysaccharide vaccine (PPV23) are variable. We evaluated uptake of PPV23 in patients diagnosed with HIV between 1996 and 2012 (n ¼ 507) in the United States Air Force, a centralized HIV program with free access to care including vaccines and medications. A total of 411 (81.1%) patients received at least 1 PPV23 dose. The PPV23 vaccination within 1 year of diagnosis was greater for those diagnosed between 2004 and 2012 (n ¼ 184, 86%) compared with 1996 to 2003 (n ¼ 104, 56.5%; P < .001). For those with 6 years of follow-up, receipt of a second recommended PPV23 dose was greater for those diagnosed between 1996 and 2003 (n ¼ 52, 57.8%) compared with 2004 to 2012 (n ¼ 9, 28.1%; P ¼ .004). Although first PPV23 vaccination was high in recent years, process improvement efforts are underway to overcome barriers and improve uptake of pneumococcal vaccines in our program.

show abstract

“…The most common technique used to study clinician adherence was a descriptive study that used a cross-sectional or retrospective chart review to measure adherence with practice guideline recommendations. [22][23][24][25][26][27] Another method used was the before-and-after observational study design with or without a concurrent control group. 19,28 In these studies, clinician adherence was measured by documentation in the clinical data base before and after implementation of an intervention designed to promote guideline adherence.…”

Section: Clinician Adherencementioning

confidence: 99%